<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/shutterstock_1859230510-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/shutterstock_1859230510-430x241.jpg"/></p>
<p>這些技術旨在恢復組織的功能並使體細胞年輕化。圖片來源：Marian Weyo/Shutterstock.com。</p>
<p>生物遺傳學公司 Klotho Neurosciences 已宣佈計劃收購 Turn Biotechnologies 的資產，這標誌着在長壽治療開發方面的一次重要舉措。</p>
<p>Turn Biotechnologies 專注於誘導多能幹細胞（iPSCs）和細胞重編程。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - 單克隆抗體結合物 3 針對 Egfr...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - CYNK-101</h4>
<h5>數據洞察</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>Klotho 已簽署意向書（LOI）。</p>
<p>現金和股票交易取決於盡職調查的完成、最終協議的簽署以及典型的成交條件的滿足。</p>
<p>根據 LOI 的條款，Klotho 將獲得對 Turn 的年齡表觀遺傳重編程（ERA）平台和 eTurna RNA 遞送系統的控制權。</p>
<p>該平台在美國斯坦福大學開發，並由該機構獨家許可，ERA 平台利用 eTurna 系統。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>由 GlobalData 提供</p>
<p>瞭解更多關於戰略情報</p>
<p>這些技術旨在恢復組織的功能並使體細胞年輕化，可能導致眼科、皮膚科、骨關節炎、肌肉健康、免疫學和肌萎縮側索硬化症（ALS）等多種再生療法。</p>
<p>交易的一個關鍵方面是 Klotho 收購與一家韓國製藥公司的外許可和聯合開發合作伙伴關係，該合作伙伴關係的價值可能高達 3 億美元。</p>
<p>這一合作展示了市場對 Turn 平台的商業興趣，強調了其技術的廣泛潛力。</p>
<p>在預計完成收購後，Klotho 計劃進行品牌重塑，以更好地代表其更廣泛的使命和治療能力。</p>
<p>該公司還計劃在交易完成後歡迎 Turn Biotechnologies 的管理和研發部門的關鍵人員。</p>
<p>Klotho Neurosciences 首席執行官 Dr Joseph Sinkule 表示：“這份 LOI 標誌着 Klotho 的一個變革性步驟。Klotho 基因通常被稱為 ‘抗衰老基因’，首次因其延長動物模型壽命和保護神經退行性疾病的能力而被識別。我們的公司成立的目的是將這一科學轉化為對抗與年齡相關的衰退的療法。”</p>
<p>“通過增加 Turn 的 ERA 技術——該技術利用六種 RNA 分子，包括四種可以重置細胞年齡的 Yamanaka 轉錄因子——以及 eTurna RNA 脂質納米顆粒（LNP）遞送平台，我們正在超越單一的 Klotho 基因，構建一個強大的細胞年輕化系統。”</p>
<h2>製藥技術卓越獎 - 參賽的好處</h2>
<p>獲得你應得的認可！製藥技術卓越獎 慶祝創新、領導力和影響力。通過參賽，你展示了你的成就，提高了你的行業形象，並將自己置於推動製藥進步的頂尖領導者之中。不要錯過脱穎而出的機會——今天就提交你的參賽作品！</p>
<p>立即提名</p>

TURN

<p>Klotho Neurosciences 計劃收購 Turn Biotechnologies 的資產，重點關注組織修復和細胞復興技術。該交易需依賴盡職調查和最終協議，包括 Turn 的年齡表觀遺傳重編程（ERA）平台和 eTurna RNA 遞送系統。這項收購可能會與一家韓國製藥公司達成價值高達 3 億美元的合作。Klotho 旨在收購後進行品牌重塑，並整合 Turn 的關鍵人員，以增強其在長壽治療領域的使命</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/shutterstock_1859230510-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/shutterstock_1859230510-430x241.jpg"/></p>
<p>The technologies are intended to restore the function of tissues and rejuvenate somatic cells. Credit: Marian Weyo/Shutterstock.com.</p>
<div class="lb-trans"><p>這些技術旨在恢復組織的功能並使體細胞年輕化。圖片來源：Marian Weyo/Shutterstock.com。</p>
</div><p>Biogenetics company Klotho Neurosciences has announced plans to acquire assets from Turn Biotechnologies, marking a move in the development of longevity therapeutics.</p>
<div class="lb-trans"><p>生物遺傳學公司 Klotho Neurosciences 已宣佈計劃收購 Turn Biotechnologies 的資產，這標誌着在長壽治療開發方面的一次重要舉措。</p>
</div><p>Turn Biotechnologies is focused on induced pluripotent stem cells (iPSCs) and cellular reprogramming.</p>
<div class="lb-trans"><p>Turn Biotechnologies 專注於誘導多能幹細胞（iPSCs）和細胞重編程。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - Monoclonal Antibody Conjugate 3 To Target Egfr...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - 單克隆抗體結合物 3 針對 Egfr...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - CYNK-101</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - CYNK-101</h4>
</div><h5>Data Insights</h5>
<div class="lb-trans"><h5>數據洞察</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Klotho has signed a letter of intent (LOI) in this regard.</p>
<div class="lb-trans"><p>Klotho 已簽署意向書（LOI）。</p>
</div><p>The cash and stock deal is contingent upon the completion of due diligence, the execution of a definitive agreement and fulfilment of typical closing conditions.</p>
<div class="lb-trans"><p>現金和股票交易取決於盡職調查的完成、最終協議的簽署以及典型的成交條件的滿足。</p>
</div><p>Under the LOI’s terms, Klotho would gain control of Turn’s Epigenetic Reprogramming of Age (ERA) platform and the eTurna RNA delivery system.</p>
<div class="lb-trans"><p>根據 LOI 的條款，Klotho 將獲得對 Turn 的年齡表觀遺傳重編程（ERA）平台和 eTurna RNA 遞送系統的控制權。</p>
</div><p>Developed at Stanford University in the US, and exclusively licensed by the institution, the ERA platform leverages the eTurna system.</p>
<div class="lb-trans"><p>該平台在美國斯坦福大學開發，並由該機構獨家許可，ERA 平台利用 eTurna 系統。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>These technologies are intended for restoring the function of tissues and rejuvenating somatic cells, potentially leading to a variety of regenerative therapies in ophthalmology, dermatology, osteoarthritis, muscle health, immunology and amyotrophic lateral sclerosis (ALS).</p>
<div class="lb-trans"><p>這些技術旨在恢復組織的功能並使體細胞年輕化，可能導致眼科、皮膚科、骨關節炎、肌肉健康、免疫學和肌萎縮側索硬化症（ALS）等多種再生療法。</p>
</div><p>A key aspect of the transaction is Klotho’s acquisition of an out-licensing and joint development partnership with a South Korean pharmaceutical company, which could be worth up to $300m.</p>
<div class="lb-trans"><p>交易的一個關鍵方面是 Klotho 收購與一家韓國製藥公司的外許可和聯合開發合作伙伴關係，該合作伙伴關係的價值可能高達 3 億美元。</p>
</div><p>This collaboration demonstrates the commercial interest in Turn’s platform, underscoring the wide-ranging potential of its technology.</p>
<div class="lb-trans"><p>這一合作展示了市場對 Turn 平台的商業興趣，強調了其技術的廣泛潛力。</p>
</div><p>Following the anticipated completion of the acquisition, Klotho plans to undergo rebranding to better represent its wider mission and therapeutic capabilities.</p>
<div class="lb-trans"><p>在預計完成收購後，Klotho 計劃進行品牌重塑，以更好地代表其更廣泛的使命和治療能力。</p>
</div><p>The company also plans to welcome key Turn Biotechnologies personnel from their management and research and development departments after the transaction is finalised.</p>
<div class="lb-trans"><p>該公司還計劃在交易完成後歡迎 Turn Biotechnologies 的管理和研發部門的關鍵人員。</p>
</div><p>Klotho Neurosciences CEO Dr Joseph Sinkule stated: “This LOI marks a transformative step for Klotho. The Klotho gene is often referred to as the ‘anti-aging gene,’ first identified for its ability to extend lifespan in animal models and protect against neurodegenerative diseases. Our company was founded on translating that science into therapies that combat age-related decline.</p>
<div class="lb-trans"><p>Klotho Neurosciences 首席執行官 Dr Joseph Sinkule 表示：“這份 LOI 標誌着 Klotho 的一個變革性步驟。Klotho 基因通常被稱為 ‘抗衰老基因’，首次因其延長動物模型壽命和保護神經退行性疾病的能力而被識別。我們的公司成立的目的是將這一科學轉化為對抗與年齡相關的衰退的療法。”</p>
</div><p>“By adding Turn’s ERA technology — which leverages six RNA molecules, including four of the Yamanaka transcription factors that can reset cellular age — together with the eTurna RNA lipid nanoparticle (LNP) delivery platform, we are expanding beyond a single Klotho gene into a powerful system of cellular rejuvenation.”</p>
<div class="lb-trans"><p>“通過增加 Turn 的 ERA 技術——該技術利用六種 RNA 分子，包括四種可以重置細胞年齡的 Yamanaka 轉錄因子——以及 eTurna RNA 脂質納米顆粒（LNP）遞送平台，我們正在超越單一的 Klotho 基因，構建一個強大的細胞年輕化系統。”</p>
</div><h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
<div class="lb-trans"><h2>製藥技術卓越獎 - 參賽的好處</h2>
</div><p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
<div class="lb-trans"><p>獲得你應得的認可！製藥技術卓越獎 慶祝創新、領導力和影響力。通過參賽，你展示了你的成就，提高了你的行業形象，並將自己置於推動製藥進步的頂尖領導者之中。不要錯過脱穎而出的機會——今天就提交你的參賽作品！</p>
</div><p>Nominate Now</p>
<div class="lb-trans"><p>立即提名</p>
</div>

Klotho 將收購 Turn Biotechnologies 的資產